Home  /  Resource Library  /  Brexucabtagene autoleucel in-vivo expansion and BTKi refractoriness have a negative influence on progression-free survival in mantle cell lymphoma: Results from CART-SIE study

Brexucabtagene autoleucel in-vivo expansion and BTKi refractoriness have a negative influence on progression-free survival in mantle cell lymphoma: Results from CART-SIE study

Study examined the effectiveness of CAR-T Brexucabtagene autoleucel in patients with MCL who received prior BTK inhibitor.